Anti-Human CD47 (Clone B6H12) – DyLight® 650

Pricing & Details

Product No.C2211
Clone
B6H12
Protein
CD47
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
IAP, OA3, neurophilin, gp42, MEM-133, CDw149, ITPG
Applications
FC
,
ICC
Prod No.
Size
Price
Avail.
Qty
Add to cart
C2211-50 µg
50 µg
$85.00
In stock
Max:
Min: 1
Step: 1
C2211-100 µg
100 µg
$150.00
In stock
Max:
Min: 1
Step: 1
C2211-200 µg
200 µg
$250.00
In stock
Max:
Min: 1
Step: 1

Antibody Details

Product Details

Reactivity Species
Human
Host Species
Mouse
Immunogen
Purified Recombinant Human CD47 (>98%)
Product Concentration
0.2 mg/ml
Formulation
This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This DyLight® 650 conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Excitation Laser
Red Laser (652 nm)
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone B6H12 recognizes an epitope on human CD47.
Antigen Distribution
CD47 is expressed on leukocytes, platelets, erythrocytes, epithelial cells, endothelial cells, fibroblasts, and is overexpressed in ovarian cancer, as well as many different tumor cells.
Background
CD47 is a 50 kD transmembrane protein receptor to the Ig superfamily that can manifest in four isoforms, differing only in the length of their cytoplasmic tail. CD47 is involved in various cellular processes including apoptosis, proliferation, adhesion, and migration, and plays a key role in immune and angiogenic responses. CD47 was first identified as a tumor antigen on human ovarian cancer and its expression has subsequently been found on multiple human tumor types such as acute myeloid leukemia (AML), chronic myeloid leukemia, acute lymphoblastic leukemia (ALL), non-Hodgkin’s lymphoma (NHL), multiple myeloma (MM), bladder cancer, and pediatric and adult brain tumors. CD47 interacts with membrane integrins, TSP-1, and SIRPα. The CD47/SIRPα interaction results in the inhibition of phagocytosis by macrophages thus, allowing cancer cells to multiply unchecked. Anti-CD47 antibody is a potential therapeutic target in a variety of cancers and for the treatment of pulmonary fibrosis. Anti-CD47 antibody treatment not only facilitates macrophage phagocytosis of cancer, but also promotes the activation of cancer-specific lymphocytes by acting as a beacon, flagging cancer cells which now display altered proteins to which the immune system can react.

Antigen Details

Protein
Ligand/Receptor
Non-covalently associated with ß3 integrins CD51/CD61, CD41/CD61. Thrombospondin is a ligand for CD47.
PubMed
NCBI Gene Bank ID
Research Area
Immunology
Flow Cytometry

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Cookie Policy
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy.